FENC
Fennec Pharmaceuticals Inc. · Healthcare
6.24
2.88%(-0.18)
Market OpenLast Updated: — ET
52W L: $4.6852W H: $9.92
$6.23
CHG-1.64 (-20.84%)
H$8.16
L$5.68
VOL3.5M
FENC (1h)
Fennec Pharmaceuticals Inc. · Healthcare
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 377,500 of the Company's common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Adherex Technologies (NASDAQ: FENC - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of $0.0423 per share and revenue of $14.7490 million for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigation focuses on Fennec Pharmaceuticals executive officers and whether investor losses may be recovered under federal securities laws.
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Cioffi Christiana Marie
officer: Chief Strategy Officer
120,000 SH @ $5.77
2026-03-31
Cioffi Christiana Marie
officer: Chief Strategy Officer
1,901 SH @ $0.00
2026-03-28
Cioffi Christiana Marie
officer: Chief Strategy Officer
158 SH @ $0.00
2026-03-31
Cioffi Christiana Marie
officer: Chief Strategy Officer
17,106 SH @ $0.00
2026-03-31
Hackman Jeffrey S.
director, officer: Chief Executive Officer
200,000 SH @ $5.77
2026-03-31
Hackman Jeffrey S.
director, officer: Chief Executive Officer
13,943 SH @ $0.00
2026-03-28
Hackman Jeffrey S.
director, officer: Chief Executive Officer
1,159 SH @ $0.00
2026-03-31
Hackman Jeffrey S.
director, officer: Chief Executive Officer
16,695 SH @ $0.00
2026-03-31